Portland, Ore. – BCDI’s team of expert physicians and research specialists spent March 19 – 21 at the Thrombosis & Hemostasis Summit of North America (THSNA) presenting cutting edge research findings across various bleeding and blood clotting disorders.

 

Presentations

BCDI Chief Executive & Medical Officer Dr. Michael Tarantino and BCDI Associate Medical & Research Director Dr. Jonathan Roberts led in-person presentations during THSNA 2026:

  • Dr. Tarantino
    • Session Name: Redefining Guidance on Bleeding Disorders in Sports
      • Presentation Title: Developing a Shared Decision Plan Prior to Training/Sports Activity
  • Dr. Roberts
    • Session Name: Clinical Considerations: Aging with a Bleeding Disorder
      • Presentation Title: Cardiovascular Considerations & Drug Interactions in the Care of Bleeding Disorders

 

Posters

The BCDI team also had poster/abstracts on show at THSNA 2026, led by Dr. Roberts and the research staff at BCDI. Posters presented include:

  • Emicizumab for Severe Von Willebrand Disease (VWD): The EMIVWD Study
    • Dr. Roberts is the Principal Investigator for this study, alongside Dr. Tarantino and BCDI Research Department members Dayna Lenski and Sara Malik.
      • Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, typically characterized by mucocutaneous bleeding. Prophylaxis for VWD with severe bleeding phenotypes currently has limited treatment options, and non-intravenous therapeutics are desired to tailor therapy. Emicizumab is a monoclonal, bispecific antibody that demonstrates factor VIII-like activity enhancing thrombin generation, transforming prophylactic therapy for many with hemophilia A. Emicizumab is administered subcutaneously less frequently than other currently available VWD therapeutics. Based on available literature emicizumab has been utilized successfully for VWD prophylaxis, and further investigation is warranted. The objective is to evaluate the safety and efficacy of emicizumab for prophylaxis in severe VWD compared to the preceding 12-month bleed history. This ongoing pilot study is the first prospective investigation of emicizumab in patients with severe VWD.  This study will shed light on feasibility, safety and potential efficacy of emicizumab prophylaxis in this patient population.
        • This study’s enrollment is OPEN! If you believe you would be qualified to enroll to participate in the EMIVWD Study or would like to learn more, please reach out to the BCDI Research team via email at research@ilbcdi.org or visit the study overview webpage.
  • Healthcare Resource Utilization in People With Hemophilia Treated Within Vs. External to U.S. Hemophilia Treatment Center Network Clinics: An Update from the CHESS US Study
    • Dr. Roberts is one of eight researchers on this study.
      • People with hemophilia (PwH) in the United States may receive comprehensive care through the Hemophilia Treatment Center Network (USHTCN).  Little information on non-USHTCN clinics is available. Characterizing outcomes and healthcare resource utilization (HCRU) in PwH treated in non-USHTCN clinics is key to improving health outcomes. This analysis aimed to characterize clinical and HCRU outcomes for PwH treated at USHTCN and non-USHTCN clinics and identify potential elements driving inconsistencies across settings.  This study concludes that the non-USHTCN cohort had higher prevalence of anemia/fatigue in non-USHTCN PwH and significantly increased hospital visits, hospitalization duration, and much higher reliance of on emergency services. Higher HCRU is likely to increase cost of care and out of pocket expenses, particularly in under/un-insured PwH. USHTCN staff often act as insurance navigators, helping PwH find appropriate coverage, reducing the economic burden on PwH and the healthcare system.